Thursday, November 14, 2013

Seeking Alpha: With "Progress" Like Lexicon's, Who Needs Failure?

Another quarter is in the books and the biggest (and some might say "only") question around Lexicon Pharmaceuticals (LXRX) remains unanswered. While it has been almost a year and a half since the company first reported Phase II data on its experimental diabetes drug LX4211 ('4211), the company has yet to finalize and announce the partnering agreement that will be key to advancing the drug into pivotal studies. While there is still meaningful potential value in this drug (including the possibility of a differentiated efficacy and safety profile that could significantly boost its peak sales), time and patience are getting shorter.

Please continue here:
With "Progress" Like Lexicon's, Who Needs Failure?

No comments: